10 June 2021 · The below summary explains the legislation and guidance on the use of PGDs when a medicine is to be used outside its licence ('off-label')
16 March 2021 · This Q&A has been developed with the MHRA and it reflects MHRA guidance on the use of PGDs for medications which have risk minimisation measures (RMM).
9 September 2020 · This Q&A provides advice on the legal considerations required when considering mixing medicines to be supplied or administered under a PGD
8 January 2020 · The below summary details the legal position regarding the sale, supply or administration of off-label/ unlicenced products under Schedule 17 of the HMR 2012